Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase 1 study of latozinemab in progranulin‐associated frontotemporal dementia

1 Jan 2024

Abstract excerpt

Abstract INTRODUCTION Heterozygous mutations in the GRN gene lead to reduced progranulin (PGRN) levels in plasma and cerebrospinal fluid (CSF) and are causative of frontotemporal dementia (FTD) with > 90% penetrance. Latozinemab is a human monoclonal immunoglobulin G1 antibody that is being developed to increase PGRN levels in individuals with FTD caused by heterozygous loss‐of‐function GRN mutations. METHODS A...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Amyotrophic Lateral Sclerosis Research
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38356474
DOI: 10.1002/trc2.12452

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase 1 study of latozinemab in progranulin‐associated frontotemporal dementiaPMID 38356474Read ↗

Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia.Semantic proximity Read ↗

Frontotemporal dementia as a consequence of GRN mutations: From disease cause to models to therapies.Semantic proximity Read ↗

Clinical investigation of VES001, a novel oral small molecule sortilin receptor inhibitor, for the treatment of frontotemporal dementiaSemantic proximity Read ↗

Progranulin: an emerging target for FTLD therapies.Semantic proximity Read ↗

New insights and therapeutic opportunities for progranulin-deficient frontotemporal dementia.Semantic proximity Read ↗

Plasma progranulin levels for frontotemporal dementia in clinical practice: a 10-year French experience.Semantic proximity Read ↗

A systematic review of progranulin concentrations in biofluids in over 7,000 people-assessing the pathogenicity of GRN mutations and other influencing factors.Semantic proximity Read ↗

Progranulin and TMEM106B: when two become wan.Semantic proximity Read ↗

Cerebrospinal Fluid Progranulin, but Not Serum Progranulin, Is Reduced in GRN-Negative Frontotemporal Dementia.Semantic proximity Read ↗

Potential mechanisms of progranulin-deficient FTLD.Semantic proximity Read ↗

Progranulin as a therapeutic target in neurodegenerative diseases.Semantic proximity Read ↗

Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.